Current Psychiatry Reports

, Volume 4, Issue 3, pp 177–184 | Cite as

Stimulant-induced psychosis and schizophrenia: The role of sensitization

  • Hiroshi Ujike


Three different conditions, psychostimulant-induced behavioral sensitization in rodents, psychostimulantinduced psychoses in human, and chronic schizophrenia show similar longitudinal alternations, progressively enhanced susceptibility to abnormal behaviors, psychotic state, and relapse. Sensitization phenomena to the drugs or endogenous dopamine should be involved in the mechanisms underlying the development of such susceptibility. Recently, an enhanced dopamine release in vivo by amphetamine administration in the striatum has been shown in schizophrenics, which is a replication of that previously proven in the behavioral sensitization in rats. Accordingly, common molecular mechanisms of sensitization phenomena must develop in these three conditions, and are overviewed in this review.


Schizophrenia Cocaine Amphetamine Methamphetamine Behavioral Sensitization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Akiyama K, Kanzaki A, Tsuchida K, et al.: Methamphetamineinduced behavioral sensitization and its implications for relapse of schizophrenia. Schizophr Res 1994, 12:251–257.PubMedCrossRefGoogle Scholar
  2. 2.
    Robinson TE, Becker JB: Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986, 11:157–198.CrossRefGoogle Scholar
  3. 3.
    Laruelle M: The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000, 31:371–384. An important article.PubMedCrossRefGoogle Scholar
  4. 4.
    Paulson PE, Camp DM, Robinson TE: Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991, 103:480–492.PubMedCrossRefGoogle Scholar
  5. 5.
    Hooks MS, Jones DN, Holtzman SG, et al.: Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpirole. Psychopharmacology 1994, 116:217–225.PubMedCrossRefGoogle Scholar
  6. 6.
    Alexander RC, Wright R, Freed W: Quantitative trait loci contributing to phencyclidine-induced and amphetamineinduced locomotor behavior in inbred mice. Neuropsychopharmacology 1996, 15:484–490.PubMedCrossRefGoogle Scholar
  7. 7.
    Cunningham ST, Finn M, Kelley AE: Sensitization of the locomotor response to psychostimulants after repeated opiate exposure: role of the nucleus accumbens. Neuropsychopharmacology 1997, 16:147–155.PubMedCrossRefGoogle Scholar
  8. 8.
    Lamarque S, Taghzouti K, Simon H: Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001, 41:118–129.PubMedCrossRefGoogle Scholar
  9. 9.
    Horger BA, Giles MK, Schenk S: Preexposure to amphetamine and nicotine predisposes rats to self-administer a low dose of cocaine. Psychopharmacology 1992, 107:271–276.PubMedCrossRefGoogle Scholar
  10. 10.
    Antelman SM, Eichler AJ, Black CA, et al.: Interchangeability of stress and amphetamine in sensitization. Science 1980, 207:329–331.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaham Y, Erb S, Stewart J: Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev 2000, 33:13–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Sato M, Chen CC, Akiyama K, et al.: Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983, 18:429–440.PubMedGoogle Scholar
  13. 13.
    Tatetsu S: Methamphetamine psychosis. Folia Pstchiatr Neurol Jpn Suppl 1963, 7:377–380.Google Scholar
  14. 14.
    Satel SL, Edell WS: Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991, 148:1708–1711.PubMedGoogle Scholar
  15. 15.
    Ohmori T, Ito K, Abekawa T, et al.: Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up. Eur Arch Psychiatry Clin Neurosci 1999, 249:73–78. A good review.PubMedCrossRefGoogle Scholar
  16. 16.
    Lieberman JA, Kane JM, Alvir J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987, 91:415–433.PubMedCrossRefGoogle Scholar
  17. 17.
    Lieberman JA, Kane JM, Sarantakos S, et al.: Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987, 44:597–603.PubMedGoogle Scholar
  18. 18.
    Kazahaya Y, Akimoto K, Otsuki S: Subchronic methamphetamine treatment enhances methamphetamine- or cocaineinduced dopamine efflux in vivo. Biol Psychiatry 1989, 25:903–912.PubMedCrossRefGoogle Scholar
  19. 19.
    Akimoto K, Hamamura T, Otsuki S: Subchronic cocaine treatment enhances cocaine-induced dopamine efflux, studied by in vivo intracerebral dialysis. Brain Res 1989, 490:339–344.PubMedCrossRefGoogle Scholar
  20. 20.
    Akimoto K, Hamamura T, Kazahaya Y, et al.: Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine: an in vivo dialysis study in freely moving rats. Brain Res 1990, 507:344–346.PubMedCrossRefGoogle Scholar
  21. 21.
    Robinson TE, Jurson PA, Bennett JA, et al.: Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 1988, 462:211–222.PubMedCrossRefGoogle Scholar
  22. 22.
    Hamamura T, Akiyama K, Akimoto K, et al.: Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis. Brain Res 1991, 546:40–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Ujike H, Onoue T, Akiyama K, et al.: Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 1989, 98:89–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Karler R, Calder LD, Chaudhry IA, et al.: Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 1989, 45:599–606.PubMedCrossRefGoogle Scholar
  25. 25.
    Wolf ME, White FJ, Hu XT: MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J Neurosci 1994, 14:1735–1745.PubMedGoogle Scholar
  26. 26.
    Laruelle M, Abi-Dargham A, van Dyck CH, et al.: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996, 93:9235–9240.PubMedCrossRefGoogle Scholar
  27. 27.
    Breier A, Su TP, Saunders R, et al.: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94:2569–2574.PubMedCrossRefGoogle Scholar
  28. 28.
    Terwilliger RZ, Beitner JD, Sevarino KA, et al.: A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 1991, 548:100–110.PubMedCrossRefGoogle Scholar
  29. 29.
    Nestler EJ, Aghajanian GK: Molecular and cellular basis of addiction. Science 1997, 278:58–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Greengard P, Allen PB, Nairn AC: Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435–447.PubMedCrossRefGoogle Scholar
  31. 31.
    Cunningham ST, Kelley AE: Hyperactivity and sensitization to psychostimulants following cholera toxin infusion into the nucleus accumbens. J Neurosci 1993, 13:2342–2350.PubMedGoogle Scholar
  32. 32.
    Miserendino MJ, Nestler EJ, Behavioral sensitization to cocaine: modulation by the cyclic AMP system in the nucleus accumbens. Brain Res 1995, 674:299–306.PubMedCrossRefGoogle Scholar
  33. 33.
    Steketee JD: Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 1994, 6:69–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Tolliver BK, Ho LB, Reid MS, et al.: Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants. J Pharmacol Exp Ther 1996, 278:411–420.PubMedGoogle Scholar
  35. 35.
    Brandon EP, Logue SF, Adams MR, et al.: Defective motor behavior and neural gene expression in RIIbeta-protein kinase A mutant mice. J Neurosci 1998, 18:3639–3649.PubMedGoogle Scholar
  36. 36.
    Xue CJ, Ng JP, Li Y, et al.: Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J Neurochem 1996, 67:352–363.PubMedCrossRefGoogle Scholar
  37. 37.
    Licata SC, Freeman AY, Pierce-Bancroft AF, et al.: Repeated stimulation of L-type calcium channels in the rat ventral tegmental area mimics the initiation of behavioral sensitization to cocaine. Psychopharmacology 2000, 152:110–118.PubMedCrossRefGoogle Scholar
  38. 38.
    Karler R, Turkanis SA, Partlow LM, et al.: Calcium channel blockers and behavioral sensitization. Life Sci 1991, 49:165–170.PubMedCrossRefGoogle Scholar
  39. 39.
    Itzhak Y: Modulation of cocaine- and methamphetamineinduced behavioral sensitization by inhibition of brain nitric oxide synthase. J Pharmacol Exp Ther 1997, 282:521–527.PubMedGoogle Scholar
  40. 40.
    Itzhak Y, Ali SF, Martin JL, et al.: Resistance of neuronal nitric oxide synthase-deficient mice to cocaine-induced locomotor sensitization. Psychopharmacology 1998, 140:378–386.PubMedCrossRefGoogle Scholar
  41. 41.
    Pierce RC, Bell K, Duffy P, et al.: Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci 1996, 16:1550–1560.PubMedGoogle Scholar
  42. 42.
    Horger BA, Iyasere CA, Berhow MT, et al.: Enhancement of locomotor activity and conditioned reward to cocaine by brainderived neurotrophic factor. J Neurosci 1999, 19:4110–4122.PubMedGoogle Scholar
  43. 43.
    Pierce RC, Pierce-Bancroft AF, Prasad BM: Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/Mitogen-activated protein kinase signal transduction cascade. J Neurosci 1999, 19:8685–8695.PubMedGoogle Scholar
  44. 44.
    Berhow MT, Hiroi N, Nestler EJ: Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J Neurosci 1996, 16:4707–4715.PubMedGoogle Scholar
  45. 45.
    Wang XB, Funada M, Imai Y, et al.: rGbeta1: a psychostimulant-regulated gene essential for establishing cocaine sensitization. J Neurosci 1997, 17:5993–6000.PubMedGoogle Scholar
  46. 46.
    Takaki M, Ujike H, Kodama M, et al.: Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differently activated by acute and chronic methamphetamine treatment in the rat brain. J Neurochem 2001, 79:679–688. A good article.PubMedCrossRefGoogle Scholar
  47. 47.
    Ujike H, Takaki M, Kuroda S: Neural plasticity-related genes and the behavioral sensitization phenomenon. Psychiatry Clin Neurosci 2002, In press.Google Scholar
  48. 48.
    Carlezon WA, Jr., Thome J, Olson VG, et al.: Regulation of cocaine reward by CREB. Science 1998, 282:2272–2275. An important review.PubMedCrossRefGoogle Scholar
  49. 49.
    Walters CL, Blendy JA: Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. J Neurosci 2001, 21:9438–9444.PubMedGoogle Scholar
  50. 50.
    Hope BT, Nye HE, Kelz MB, et al.: Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994, 13:1235–1244.PubMedCrossRefGoogle Scholar
  51. 51.
    Chen J, Kelz MB, Hope BT, et al.: Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci 1997, 17:4933–4941.PubMedGoogle Scholar
  52. 52.
    Bibb JA, Chen J, Taylor JR, et al.: Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 2001, 410:376–380. A good article.PubMedCrossRefGoogle Scholar
  53. 53.
    Hiroi N, Fienberg AA, Haile CN, et al.: Neuronal and behavioral abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci 1999, 11:1114–1118.PubMedCrossRefGoogle Scholar
  54. 54.
    Kelz MB, Chen J, Carlezon WJ, et al.: Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature 1999, 401:272–276. A good article.PubMedCrossRefGoogle Scholar
  55. 55.
    Hiroi N, Brown JR, Haile CN, et al.: FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine’s psychomotor and rewarding effects. Proc Natl Acad Sci U S A 1997, 94:10397–10402.PubMedCrossRefGoogle Scholar
  56. 56.
    Karler R, Finnegan KT, Calder LD: Blockade of behavioral sensitization to cocaine and amphetamine by inhibitors of protein synthesis. Brain Res 1993, 603:19–24.PubMedCrossRefGoogle Scholar
  57. 57.
    Shimosato K, Saito T: Suppressive effect of cycloheximide on behavioral sensitization to methamphetamine in mice. Eur J Pharmacol 1993, 234:67–75.PubMedCrossRefGoogle Scholar
  58. 58.
    Fujiwara Y, Kazahaya Y, Nakashima M, et al.: Behavioral sensitization to methamphetamine in the rat: an ontogenic study. Psychopharmacology 1987, 91:316–319.PubMedCrossRefGoogle Scholar
  59. 59.
    Ujike H, Tsuchida K, Akiyama K, et al.: Ontogeny of behavioral sensitization to cocaine. Pharmacol Biochem Behav 1995, 50:613–617.PubMedCrossRefGoogle Scholar
  60. 60.
    Robinson TE, Kolb B: Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 1997, 17:8491–8497. A good review.PubMedGoogle Scholar
  61. 61.
    Robinson TE, Kolb B: Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 1999, 11:1598–1604.PubMedCrossRefGoogle Scholar
  62. 62.
    Takaki M, Ujike H, Kodama M, et al.: Increased expression of synaptophysin and staathmin mRNAs after methamphetamine administration in rat brain. Neuroreport 2001, 12:1055–1060.PubMedCrossRefGoogle Scholar
  63. 63.
    Denovan-Wright EM, Newton RA, Armstrong JN, et al.: Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat. Mol Brain Res 1998, 55:350–354.PubMedCrossRefGoogle Scholar
  64. 64.
    Iwata S, Hewlett GH, Ferrell ST, et al.: Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine. J Pharmacol Exp Ther 1996, 278:1428–1434.PubMedGoogle Scholar
  65. 65.
    Kodama M, Akiyama K, Ujike H, et al.: A robust increase in expression of arc gene, an effector immediate early gene, in the rat brain after acute and chronic methamphetamine administration. Brain Res 1998, 796:273–283.PubMedCrossRefGoogle Scholar
  66. 66.
    Ujike H, Takaki M, Kodama M, et al.: Gene expression related to synaptogenesis, neuritogenesis, and MAP kinase in behavioral sensitization to psychostimulants. Ann N Y Acad Sci 2002, In press. A good review.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Hiroshi Ujike
    • 1
  1. 1.Department of NeuropsychiatryOkayama University Graduate School of Medicine and DentistryOkayamaJapan

Personalised recommendations